Peptide-Conjugated Lipid Membranes Traversing Endothelial Tight Junctions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid membrane structures and peptide carriers face challenges in traversing tight junctions of vascular endothelial cells, leading to difficulties in delivering substances to target sites due to limited cell permeability and potential side effects.
Innovation Solution
Development of peptides with specific amino acid sequences, such as LX1X2X1X1L, LLX2X1X1X1L, or LX1X2X1X1L, where L represents leucine, X1 is a polar amino acid, and X2 is a polar, non-charged, and branched chain amino acid, which impart or enhance cell permeability to lipid membrane structures, allowing them to traverse epithelial cells and reach target sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a high-molecular compound such as a lipid membrane structure is administered into the blood, then the substance is protected from decomposition and side effects are prevented, but it is difficult for the compound to reach the target site through the tight junction between vascular endothelial cells
Solution Approach 1:
The patent modifies the surface properties of the lipid membrane structure by conjugating specific peptides (such as ICAM-1 binding peptides) to its surface. This parameter change enables the structure to interact with and traverse the tight junction between vascular endothelial cells through receptor-mediated transcytosis, while maintaining the protective encapsulation function.
Solution Approach 2:
The patent introduces peptide mediators that serve as intermediaries between the lipid membrane structure and the vascular endothelial cells. These peptides bind to specific receptors (such as ICAM-1) on the endothelial cell surface, facilitating the transport of the encapsulated substance across the tight junction to the target site.
2Productivity
If viral vectors are used for introducing genes into target cells, then gene delivery efficiency is improved, but difficult large-scale production, antigenicity, and toxicity occur
Solution Approach 1:
The patent replaces complex viral vectors with non-viral lipid membrane structures that can be easily synthesized and produced at large scale. These liposomal carriers, while having shorter persistence in the body, achieve effective gene delivery through peptide-mediated transcytosis and cellular uptake mechanisms, avoiding the production and safety issues of viral vectors.
Solution Approach 2:
The patent creates composite delivery systems by combining lipid membrane structures with functional peptides and nucleic acids. This composite approach achieves gene delivery capabilities similar to viral vectors while maintaining the advantages of easier production, lower immunogenicity, and reduced toxicity of non-viral carriers.
Data Source
AI summary
Provided are peptides imparting cell permeability to a lipid membrane structure and/or enhancing the cell permeability of a lipid membrane structure, and a lipid membrane structure which comprises, as a constituent lipid, a lipid bound to such a peptide and has cell permeability or shows enhanced cell permeability. The amino acid sequences of the peptides imparting cell permeability to a lipid membrane structure and/or enhancing the cell permeability of a lipid membrane structure are represented by: LX1X2X1X1X1L, LLX2X1X1X1L and LX1X2X1X1L (wherein L represents a leucine residue; X1 represents a polar amino acid residue; and X2 represents a polar, non-charged and branched chain amino acid residue).